Accera, Inc. Announces Data Presentation at the Annual Meeting of the American Association for Geriatric Psychiatry (AAGP) 2012

BROOMFIELD, Colo., March 18, 2012 /PRNewswire/ -- Accera, Inc., a privately-held, commercial-stage, healthcare company focused on the discovery and development of innovative therapeutics to treat central nervous system disorders, announced today that a poster highlighting retrospective data about the company's product Axona® will be presented during the Annual Meeting of the American Association for Geriatric Psychiatry (AAGP) 2012 in Washington, D.C., March 15-19, 2012.

The poster, entitled "Retrospective Evaluation of Constructional Praxis Measurements Among APOE4(-) Subjects Enrolled in the Study of AC-1202 (Axona) in Mild-to-Moderate Alzheimer's Disease (AD)," describes the effects of Axona, a medical food, in subjects with mild-to-moderate AD.  David W. Crumpacker, MD, will present the poster on Sunday, March 18, 2012 at 4:30 p.m. EDT in the Exhibit Hall of the Washington Hilton in Washington, D.C.

Holger Kunze, president and CEO of Accera, said, "The data presented at this year's AAGP meeting demonstrate Accera's ongoing commitment to providing alternative and cutting-edge therapeutics for Alzheimer's patients and their families."

The results of the retrospective analysis showed that administration of Axona increased performance in tests of an individual's ability to assemble or join parts to form a single object, such as drawing a three dimensional cube, when compared to participants on placebo.  This ability is called constructional praxis and the ability to complete such tasks decline in AD.  In the reported study, improvement in the areas of constructional praxis occurred in non-carriers of the genetic risk factor for AD (APOE4) and lasted for two weeks after the participants stopped taking Axona.  This finding presents compelling evidence that Axona exerts real-world benefits for patients.

About Axona®
Axona is a prescription-only medical food intended for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease.  For more information about Axona, please visit www.about-axona.com or ask your physician.

About Accera, Inc.
Accera, Inc. is a privately held commercial-stage biotechnology company that developed and now markets Axona in the US.  Accera is engaged in the research, development and commercialization of other clinical applications for Axona and AC-1204 in acute and chronic neurodegenerative diseases.  For more information about Accera, please visit www.accerapharma.com.

SOURCE Accera, Inc.